Showing results (301-310 of 554) with videos related to
Sort By:
Pageof 56
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.Cancer|February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanomaRupal S Bhatt, Jaime Merchan, Robert Parker, et al.Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2012
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PETDouglas Van Nostrand, Gauri R Khorjekar, Jeff O'Neil, et al.The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.Cancer|February 1, 1994
Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibodyA K Erdi, B W Wessels, R DeJager, et al.Kidney International|May 31, 2017
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in miceHongyu Zhang, Viji Nair, Jharna Saha, et al.Behaviour Research and Therapy|June 28, 2017
Departing from the essential features of a high quality systematic review of psychotherapy: A response to Öst (2014) and recommendations for improvementPaul W B Atkins, Joseph Ciarrochi, Brandon A Gaudiano, et al.Journal of Translational Medicine|December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinomaXiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.Pageof 56